The Upcoming Trials for the First Malaria Vaccine
The World Health Organization (WHO) announced on Apr. 24, 2017 that it will conduct field trials in Ghana, Kenya, and Malawi next year on the world’s first malaria vaccine. The vaccine, known as RTS,S (Mosquirix), was developed by GlaxoSmithKline (GSK) of the United Kingdom. It is a injectable vaccine that reportedly offers partial protection against malaria in young children.
NIH to Test Mosquito Saliva Protein Vaccine Against Mosquito-Borne Diseases Like Zika
The U.S. National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) is recruiting 60 men and women for a Phase I clinical trial who will volunteer to be injected with an experimental vaccine containing synthetic proteins from mosquito saliva, then bitten by mosquitoes. The trial design is supposed to evaluate the safety and effectiveness of the new…
Gates and Pharma Head Global Coalition to Develop RNA Vaccines
America’s Bill and Melinda Gates Foundation and Great Britain’s Wellcome Trust Foundation have banded together with a handful of organizations and governments to establish and fund the Coalition for Epidemic Preparedness Innovations (CEPI) for the purpose of quickly developing new vaccines, particularly RNA…
Vaccines Against Painkiller Drugs Coming Soon
Highly addictive opioid drugs, including morphine, codeine, oxycodone, and hydrocodone, among others, are not only the most common agents used for pain management throughout the world but also are an increasingly common culprit in today’s addiction epidemic of addiction. It is not only recreational thrill seekers who get into…
Takeda To Build Dengue Vaccine Manufacturing Plant in Germany
Headquartered in Japan, Takeda Pharmaceutical Company Ltd. is the largest pharmaceutical company in Asia and is speeding up development of a vaccine for dengue fever—a mosquito-borne flavivirus disease. The Japanese drugmaker has initiated a 20,000 patient based Phase 3 study in Asia and Latin America to test its…
Major Clinical Study on HIV Vaccine Begins in South Africa
In South Africa, seven million people (one in every five) live with the Human Immunodeficiency Virus (HIV)—the virus that causes Acquired Immune Deficiency Syndrome (AIDS). Research in that country is proceeding on the development of an HIV vaccine that some believe may provide relief for those suffering from this disease.